Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01934218 · ClinicalTrials.gov registry record · NA
Gel-One Treatment in Knee Osteoarthritis
A NA study, sponsored by Seikagaku Corporation.
- Completed
- Registry status
- NA
- Development phase
- 814
- Enrollment target
NCT01934218: Completed NA study, sponsored by Seikagaku Corporation.
NCT01934218 is a NA study that has completed, run by Seikagaku Corporation. The registered enrollment target is 814 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01934218, a NA study, has completed, sponsored by Seikagaku Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 814 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Gel-One demonstrates a superior effectiveness in osteoarthritis (OA) knee pain compared with phosphate buffered saline (PBS) injections.
Primary Outcome
Observed VAS of 100 mm; 0 mm meaning no pain; 100 mm meaning extreme pain following 50-foot walk test. Change in score from baseline through week 26 was estimated using a longitudinal model.
Interventions
- DEVICE Gel-One
- DEVICE PBS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 814 participants |
| Start Date | 2013-08 |
| Est. Completion | 2016-03 |
| Phase | NA |
What the finished NCT01934218 record still lists
NCT01934218 is an interventional study that assigns participants to a tested intervention. The registered 814 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which Gel-One is the first listed.
NCT01934218 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01934218 about?
NCT01934218 is a clinical study titled "Gel-One Treatment in Knee Osteoarthritis". The purpose of this study is to determine whether Gel-One demonstrates a superior effectiveness in osteoarthritis (OA) knee pain compared with phosphate buffered saline (PBS) injections.
What is the current status of trial NCT01934218?
This trial is currently completed. It is a NA study. The enrollment target is 814 participants. The study started on 2013-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01934218?
The interventions under investigation include: Gel-One (DEVICE), PBS (DEVICE).
Who is sponsoring clinical trial NCT01934218?
This trial is sponsored by Seikagaku Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01934218's enrollment target sits among peer trials
814 134th of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT04028687 · 820 participants
MDR - PMCF Study for Taperloc Complete Stems
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia